think water agil deserv wide moat
updat forecast estim
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research
estim
price data
rate updat
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
spun hewlett-packard agil evolv
seri transact lead healthcar firm market
share leader mani core product categori especi ga
chromatographi mass spectrometri agil global
measur giant use technolog expertis global
reach serv broad base scientist custom spin
electron segment novemb name
keysight technolog agil focus sole life
scienc chemic analysi diagnost market
agil leverag competit edg electron
measur market emerg major player life
scienc market spin-off electron unit allow
agil focu chemic analysi life scienc market
present better growth opportun enhanc
compani moat higher barrier entri switch
field despit near-term challeng
constrain academ research budget weak oil ga
market agil continu benefit higher growth
among biopharma research appli industri market
also think manag priorit build diagnost
busi acquisit dako compani
smaller market share less expertis potenti
faster-grow larger clinic market opportun
agil possess larg global market distribut
infrastructur leav firm well-equip handl
competit enhanc profit oper margin
method improv sinc see gain ahead
recent effici cost-sav effort -- streamlin
suppli chain exit unprofit nmr busi enhanc
procur consolid facil outsourc noncrit
task -- boost profit make agil less suscept
swing demand compani decad ago agil
direct presenc emerg market also help solidifi custom
relationship help enhanc demand
compani product faster-growth region
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
origin spun hewlett-packard agil evolv
broad base custom within three oper segment life scienc
appli equip sale cross lab includ
consum servic diagnost genom
unit state europ account revenu
respect china japan account major remain
sale agil headquart california
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
think water agil deserv wide moat
look slightli overvalu
updat moat rate fair valu estim
agil slightli lower
fair valu estim follow modestli
disappoint result last quarter
continu favor outlook compani wide
moat meanwhil upgrad agil moat wide
base
chromatographi busi well leadership ga
chromatographi weve slightli bump agil fair
valu estim base extend second stage
model moat chang new fair valu
estim reflect impli time forward adjust
earn multipl compani
compani current look fairli valu current
market price think worth investor keep
name radar
size
thank sophist analyt requir
custom switch cost feel
agil innov disciplin capit alloc
strategi deserv wide moat agil lead gc
market -- enjoy quit high switch cost
lc market -- also come close second place
behind water lc
expect agil sustain return capit
near averag respect long
term chromatographi mass spec market
fairli matur industri forecast slightli higher growth
adjust oper margin expans
agil compani continu benefit new
product launch like intuvo gc ultivo lc-m
exposur higher growth diagnost market combin
manufactur effici effort meanwhil
forecast near growth new product like
expect launch biotof help refresh
rais fair valu estim agil per
share extend stage two length
model reflect compani wide moat rate
multipl approxim model incorpor nearli
annual growth next five year think
adjust earn grow close
time frame thank oper leverag effici effort
share repurchas
annual growth result mid-single-digit
growth agil life scienc appli divis
biopharma food industri growth along recent
recoveri energi market custom base help
off-set weaker growth academ govern
segment expect modest recoveri agil sale
improv market condit continu slowli eas
custom budget constraint especi academ
research market agil growth appli
diagnost market remain rel strong market
share gain new product launch rise
contribut emerg market also help boost
expect profit continu improv year
ahead product mix oper leverag cost-sav
initi synergi acquisit agil also
exit less profit busi nmr mri
busi acquir varian deal compani
improv economi scale life scienc
diagnost market also eventu drive
consider portion consolid margin expans
assum modest margin expans life scienc
diagnost segment lead adjust oper margin
near model assumpt culmin
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
bear case competit price pressur across
busi segment hinder growth profit
next sever year adjust oper
margin remain near expans effort stall due
strong compet platform peer slowdown
emerg market continu budgetari constraint
auster measur price pressur bear-cas fair
valu estim per share return capit
averag high teen
re-evalu outlook agil upgrad
econom moat rate wide high custom switch
cost moder barrier entri competitor
primari ingredi agil wide moat opinion
extens portfolio
intang asset
far-reach global infrastructur also critic support
compani competit advantag
agil benefit much peer
recur consum sale compani nonetheless
enjoy long product life cycl typic five year
high custom retent rate persist decad
agil cater highli skill scientist face steep
learn curv sizabl up-front invest util
special highli sensit equip
market scientist often remain loyal supplier ensur
sampl protect standard minim
reinforc high switch cost brand
research
scientif
find competit advantag agil gc-m
lc-m product line estim compani
first second place respect market share
agil lc-m busi close second place behind
five-year averag return capit high teen
estim agil cost capit approxim
award agil medium uncertainti rate thank
rel high barrier entri moder switch
cost mostli stabl product evolut
chromatographi diagnost instrument market
bull-cas scenario assum new product
launch help compani continu gain market share
agil custom maintain healthi spend
level also forecast stronger growth within asian
emerg market assum firm abl capit
strong demand trend key end segment exampl
need food safeti scenario project
compound annual growth near overal revenu
exceed billion strong price cost
control effort lead adjust oper margin
bull-cas fair valu estim per
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
industri leader estim agil share
mani attribut weve long appreci water
businessa sophist pharma custom base
depend agil highli engin instrument
product develop well qualiti control regulatori
requir approv drug lock instrument
consum long life product academ
govern custom also often demand high
precis instrument favor innov
product come agil larg portion agil
appli market base -- food chemic energi
custom tend skew toward compani gc-m
franchis -- gener less sophist instrument
perform requir switch cost persist
well train adapt workflow need
time consum expens agil particularli high
market share gc busi think
instrument reagent market tend
incorpor high level technolog complex
also keep barrier entri somewhat high opinion
addit challeng manufactur reliabl
complex instrument think necessari servic
compon
consult repair present hurdl new entrant
establish reput brand supplement exist
offer keep pace technolog advanc
agil consist alloc larg portion resourc
toward research develop sale
market
base consum make attract specialti
segment broader diagnost market
pathologist perform sophist
think agil moat support stabl posit
firm comfort oligopoli includ consist
competitor shimadzu thermo fisher
think risk disrupt
technolog low particularli matur analyt
lc gc-m instrument market see potenti
challeng ahead agil smaller clinic diagnost
segment pit power foe nimbl entrant
fragment market disrupt technolog like
genom sequenc agil may difficulti translat
histor advantag
clinic market
regardless think agil familiar competit
dynam within clinic diagnost market includ
instrument autom
regulatori matter addit agil proven
histori adapt new industri accret
acquisit
acquisit dako exampl brought signific
capabl scale within anatom patholog
market boost agil percentag recur
also see intang switch cost advantag
agil smaller diagnost divis repres
sale dako acquisit agil
roughli market share anatom patholog
market tissue-bas cancer diagnost make major
player roch compani instal
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
oagil well-establish leader mani core
familiar agil
instrument servic make market share
gain new entrant difficult
oa signific portion agil busi
depend research compos larg academ
govern institut like face
continu budget constraint near term
oagil spin-off electron measur
segment free resourc focu build
compani life scienc diagnost
chemic analysi oper -- higher-growth
differenti industri
oth acquisit dako enhanc agil
access higher-growth larger clinic
diagnost market boost compani
oagil must continu innov stay
forefront technolog advanc particularli
compet even larger compani
oacquisit divest central
compon agil strategi place high
demand manag abil execut market
expans integr goal
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
agil retain strong financi posit view
end fiscal year octob compani
billion cash balanc exceed nearli billion total debt
compani gross debt/ebitda remain around
comfort ebitda interest expens coverag ratio
greater manag continu return
signific capit sharehold dividend
share repurchas although larg acquisit
common agil manag like continu
util portion free cash flow smaller deal
award agil medium uncertainti rate thank
rel high barrier entri moder switch
cost mostli stabl product evolut
chromatographi diagnost instrument market agil
larg depend capit equip sale
volatil subject macroeconom condit
compon agil suscept capital-spend
cycl roic could risk event prolong
downturn although focus reduc relianc
agil still gener level high-margin
consum servic sale wide- narrow-moat
rival includ thermo fisher
agil also oper competit environ
establish competitor new entrant introduc better
product develop stronger relationship custom
compani may lose market share well abil
extract price increas moreov compani compet
mani smaller more-focus rival invest
signific resourc segment requir
maintain technolog edg exampl agil
current particip equip side
genom sequenc market could pose risk
road technolog potenti displac
current research clinic method regardless agil
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
larg chromatographi mass spectrometri busi
seem larg immun disrupt technolog
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
repres date owner name posit common share held report holder issuer
fidel manag research compani
share
fund
share
fund
assign compani standard mark stewardship
term capit alloc think manag wise
use acquisit divestitur keysight
technolog spin-off improv asset product
agil may aggress consolid
peer thermo fisher think
manag disciplin help uphold consist
attract return capit also believ manag
display nice track record use deal build
capabl within new market acquisit
dako exampl come steep price tag think
manag make appropri stride improv
busi asset util purchas step
stone enter higher-growth clinic diagnost arena
spin-off keysight mike mcmullen previous
presid chemic analysi segment sinc
replac william sullivan ceo agil earli
mcmullen long histori compani origin
hewlett-packard date back william sullivan
agil veteran compani sinc
spin-off hewlett-packard previous
agil ceo sinc full retir octob
sullivan remain advisori role
mcmullen transit leadership didier hirsch also
hewlett-packard veteran like mcmullen retir cfo
octob replac robert mcmahon
mcmahon previous cfo sinc
mcmullen also possess one seat agil
board director koh boon hwee -- board member sinc
jame cullen chairman board
although board switch measur
execut compens oper margin adjust
ep instead return capit think manag
compens reason option issuanc
excess
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
think water agil deserv wide moat
look slightli overvalu
updat moat rate fair valu estim
agil slightli lower
fair valu estim follow modestli
disappoint result last quarter
continu favor outlook compani wide
moat meanwhil upgrad agil moat wide
base
chromatographi busi well leadership ga
chromatographi weve slightli bump agil fair
valu estim base extend second stage
model moat chang new fair valu
estim reflect impli time forward adjust
earn multipl compani
compani current look fairli valu current
market price think worth investor keep
name radar
size
thank sophist analyt requir
custom switch cost feel
agil innov disciplin capit alloc
strategi deserv wide moat agil lead gc
market -- enjoy quit high switch cost
lc market -- also come close second place
behind water lc
expect agil sustain return capit
near averag respect long
term chromatographi mass spec market
fairli matur industri forecast slightli higher growth
adjust oper margin expans
agil compani continu benefit new
product launch like intuvo gc ultivo lc-m
exposur higher growth diagnost market combin
manufactur effici effort meanwhil
forecast near growth new product like
expect launch biotof help refresh
agil continu benefit biopharma
narrow-moat agil slightli rais year-end outlook
result
incorpor organ growth oper margin
basi point last year may
slightli increas fair valu estim modestli
boost year-end bottom-lin forecast even though
revenu adjust ep forecast billion
respect close manag current
expect billion midpoint
year manag guidanc impli organ growth
roughli fiscal fourth quarter look
conserv us despit grow concern
chines tariff depress demand rais input cost
larg see agil revenu growth margin
expans goal attain thank new product
initi includ manufactur expans nucleic
acid solut compani abil adjust supply-
chain sourc china
agil biopharma chemic energi market
remain key near-term growth driver weve seen
peer biopharma segment -- report anoth quarter
stabl organ growth agil -- continu
benefit healthi underli demand biolog
small-molecul drug research addit turnaround
chemic energi market wit past
quarter persist organ growth
quarter help strong semiconductor custom demand
similar last quarter segment continu off-set
modest weak academ environment food
segment note last quarter restructur
chines regulatori agenc hit food-rel sale
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
particularli hard anoth quarter sale declin
custom segment regardless still view mani
issu transitori current stronger
segment support mid-single-digit growth firm
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end octob
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end octob
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
